Raúl J. Andrade Bellido-rekin lankidetzan egindako argitalpenak (14)

2024

  1. Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir

    Alimentary Pharmacology and Therapeutics

  2. The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis

    Journal of Gastroenterology

2021

  1. Clinical Characteristics and Outcome of Drug-Induced Liver Injury in the Older Patients: From the Young-Old to the Oldest-Old

    Clinical Pharmacology and Therapeutics, Vol. 109, Núm. 4, pp. 1147-1158

  2. Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects

    Liver International, Vol. 41, Núm. 9, pp. 2076-2086

  3. Late presentation of chronic HBV and HCV patients seeking first time specialist care in Spain: a 2-year registry review

    Scientific Reports, Vol. 11, Núm. 1

  4. Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational Study

    American Journal of Gastroenterology, Vol. 116, Núm. 11, pp. 2250-2257

2020

  1. Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure

    Antiviral Research, Vol. 174

2019

  1. Higher levels of serum uric acid influences hepatic damage in patients with non-alcoholic fatty liver disease (NAFLD)

    Revista Española de Enfermedades Digestivas, Vol. 111, Núm. 4, pp. 264-269

  2. Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain

    PLoS ONE, Vol. 14, Núm. 11

2018

  1. Herbal and Dietary Supplement-Induced Liver Injuries in the Spanish DILI Registry

    Clinical Gastroenterology and Hepatology, Vol. 16, Núm. 9, pp. 1495-1502

2016

  1. Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury

    Journal of Hepatology, Vol. 65, Núm. 3, pp. 532-542

2015

  1. Decisiones terapéuticas en el tratamiento del carcinoma hepatocelular y patrones de uso de sorafenib. Resultados del estudio internacional observacional GIDEON en España

    Gastroenterologia y Hepatologia, Vol. 38, Núm. 4, pp. 263-273

  2. Perfil clínico y seguimiento de los pacientes con hepatitis C crónica en hospitales españoles: Estudio disHCovery

    Revista Espanola de Quimioterapia, Vol. 28, Núm. 3, pp. 145-153

2004

  1. Genotipo y expresión fenotípica de la hemocromatosis hereditaria en España

    Gastroenterologia y Hepatologia, Vol. 27, Núm. 8, pp. 437-443